R

Reata Pharmaceuticals Inc
F:2R3

Watchlist Manager
Reata Pharmaceuticals Inc
F:2R3
Watchlist
Price: 161 EUR
Market Cap: 6B EUR

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of 2R3.

The Intrinsic Value is calculated as the average of DCF and Relative values:

2R3 Intrinsic Value
Not Available
R
Base Case Scenario
Compare 2R3 to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about 2R3?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Reata Pharmaceuticals Inc

Current Assets 401.8m
Cash & Short-Term Investments 330.2m
Receivables 22.7m
Other Current Assets 49m
Non-Current Assets 100.7m
PP&E 89.9m
Other Non-Current Assets 10.8m
Current Liabilities 125.1m
Accounts Payable 19.9m
Accrued Liabilities 27.6m
Other Current Liabilities 77.6m
Non-Current Liabilities 290.2m
Long-Term Debt 73.1m
Other Non-Current Liabilities 217.1m
Efficiency

Free Cash Flow Analysis
Reata Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Reata Pharmaceuticals Inc

Revenue
23.5m USD
Cost of Revenue
-1.6m USD
Gross Profit
21.9m USD
Operating Expenses
-363.6m USD
Operating Income
-341.7m USD
Other Expenses
254m USD
Net Income
-87.6m USD
Fundamental Scores

2R3 Profitability Score
Profitability Due Diligence

Reata Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

40/100
Profitability
Score

Reata Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

2R3 Solvency Score
Solvency Due Diligence

Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
42/100
Solvency
Score

Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

2R3 Price Targets Summary
Reata Pharmaceuticals Inc

There are no price targets for 2R3.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 2R3 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y